Status:
COMPLETED
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Lead Sponsor:
Pfizer
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated...
Detailed Description
The specific objectives of the study are as follows: Describe incident adverse events (AEs) experienced among patients with advanced RCC who received first-line axitinib in combination with immuno-on...
Eligibility Criteria
Inclusion
- Physicians meeting the following criteria will be invited to participate in the chart review study:
- Specialty in oncology
- Access to complete medical records for at least one patient with advanced RCC who meets the patient eligibility criteria
- Eligible oncologists will be asked to select up to three patients meeting the following criteria for inclusion in the chart review study:
- Confirmed diagnosis with advanced RCC
- Treated with first-line axitinib/IO combination therapy at or after diagnosis
- Experienced at least one AE (i.e., diarrhea, fatigue, nausea, hypertension, and palmar-plantar erythrodysesthesia \[hand-foot syndrome\]) while treated with axitinib/IO combination therapy
- Age 18 years or older at the time of advanced RCC diagnosis
- Initiated axitinib/IO combination therapy at least 3 months prior to the start date of medical chart abstraction to ensure sufficient follow-up time
Exclusion
- There are no exclusion criteria for this study
Key Trial Info
Start Date :
February 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 5 2021
Estimated Enrollment :
481 Patients enrolled
Trial Details
Trial ID
NCT04682587
Start Date
February 24 2021
End Date
April 5 2021
Last Update
January 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
New York, New York, United States, 10017